Benzodiazepines Deprescribing in the Community Setting: Intervention Feasibility

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-05-23

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this feasibility study is to evaluate the feasibility of an intervention, led by the pharmacist, aiming at benzodiazepines and z-drugs deprescribing in older adults living in the Belgian community setting. The main questions it aims to answer are:

* To what extent will Belgian community pharmacists adhere to the intervention?
* To what extent will patients and general practitioners take up the intervention to deprescribe benzodiazepines and z-drugs?
* To what extent is the design of the recruitment and data collection process feasible and acceptable for all participants?

Participants will receive an educational brochure from their pharmacist. Their pharmacist will also propose to send a new standardized form to their general practitioner to enhance collaboration about a potential benzodiazepine deprescribing.

Researchers will compare this intervention to usual care to see if the intervention is feasible and to gather first data on intervention effectiveness in benzodiazepine deprescribing.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Impact of a Pharmacist Intervention on Post-discharge Hypnotic Drug Discontinuation in Geriatric Inpatients

NCT05521971

Hypnotic Withdrawal

COMPLETED NA

Implementation Strategies for a Simple Intervention to Reduce Longterm Benzodiazepine Use in Dutch Community Pharmacies

NCT00268775

Benzodiazepines Therapeutic Use

COMPLETED NA

Medication Review Focusing on Anticoagulation Therapy in Swiss Community Pharmacies

NCT02703727

Drug Therapy Management

COMPLETED

Electronic Deprescribing Tool for the Prevention of PIP

NCT03192514

Prevention Benzodiazepine Dependence

TERMINATED NA

Obstacles to Deprescribing Among French Patients Over 75 Years of Age Treated in the Geriatric Hospital Network

NCT05327634

Medication Abuse

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Benzodiazepine Deprescribing

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

END-IT intervention for the community setting

The community pharmacist will distribute an educational brochure to the patient. He will also propose to the patient to communicate about a potential benzodiazepine deprescribing with his/her general practitioner through a document called pharmaceutical proposal.

Group Type EXPERIMENTAL

END-IT intervention for the community setting

Intervention Type OTHER

The intervention was described in the arm/group descriptions.

Control

The participants will receive the usual care. The community pharmacists allocated to the control group will have access to the intervention material at the end of the study.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

END-IT intervention for the community setting

The intervention was described in the arm/group descriptions.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* being aged ≥65 years,
* taking a benzodiazepine receptor agonist for ≥4 weeks (Anatomical Therapeutic Chemical codes: N05BA, N05CD, N05CF and N03AE01)
* being a regular patient of the community pharmacy (defined as ≥ 4 visits/12 previous months).

Exclusion Criteria

* Severe mental illness (assessed through having an active prescription of any antipsychotic medication).
* Dementia or significant cognitive impairment (assessed through an active prescription or any past prescription during the last 12 months of anticholinesterase inhibitors or memantine) and/or pharmacist's judgment).
* Patients unable to read or communicate in French.
* Ongoing benzodiazepine receptor agonist withdrawal at the time of recruitment.
* Known current alcohol withdrawal.

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No